Nadal, EBosch-Barrera, JCedrés, SCoves, JGarcía-Campelo, RGuirado, MLópez-Castro, ROrtega, A LVicente, Dde Castro-Carpeño, J2023-02-092023-02-092021-02-04http://hdl.handle.net/10668/17102Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Clinical guidelinesDiagnosticMalignant pleural mesotheliomaTreatmentAntineoplastic AgentsAsbestosCarcinogensCombined Modality TherapyCytoreduction Surgical ProceduresDeoxycytidineGenetic TestingHigh-Throughput Nucleotide SequencingHumansImmunotherapyMedical OncologyMesothelioma, MalignantNeoplasm StagingPemetrexedPlatinum CompoundsPleural NeoplasmsRadiotherapySocieties, MedicalSpainVinorelbineGemcitabineresearch article33538989open access10.1007/s12094-020-02532-21699-3055PMC8057959https://link.springer.com/content/pdf/10.1007/s12094-020-02532-2.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057959/pdf